Leading GSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer TrialsOrphan Drug Designation in Soft Tissue Sarcomas Expands Company’s Potential to Address Cancers ...

According to Dr. Steven D. Reich, Senior VP of Clinical Development and Acting Chief Medical Officer at Actuate, the current first-line systemic treatment for metastatic STS is doxorubicin ...

(NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical ... Doxorubicin, approved almost 50 years ago, remains the recommended 1 st line systemic treatment despite exhibiting minimal ...

Actuate Therapeutics (ACTU) has filed for up to 2,777,778 share offering by selling stockholders.

Doxorubicin, approved almost 50 years ago, remains the recommended 1 st line systemic treatment despite exhibiting minimal antitumor activity highlighting the unmet medical need for patients with ...

After hours: September 23 at 7:21 PM EDT Loading Chart for LINE ...

Investopedia / Zoe Hansen Money line bets are wagers placed on a game’s outcome. In essence, they are bets on which team or competitor will win any given match. As the wager is on who will win ...

Actuate Therapeutics has won Food and Drug Administration orphan-drug designation for its lead investigational drug product in a group of rare cancerous tumors. Actuate on Wednesday said the ...